Stocks · Health care · Biological Products, (No Diagnostic Substances)

Taysha Gene Therapies, Inc.

TSHA Clue Score55
United States Fiscal year ends December CIK 0001806310 Results filed 11 Aug 2026

What the insiders did No buying or selling

By person

8 insiders · 0 transactions
28.0×

Sean Nolan holds 28.0 times base salary in stock. $18.15M of shares against $645.84K in salary for 2025.

Salary from the company's own proxy. The shares are what Sean Nolan last reported holding, valued at $6.24, the price Common Stock was last bought or sold at on the open market here, on 10 Jul 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Sean P. Nolan
Chief Executive Officer
—
—
—
2,908,257
$18.15M
+145.2%
Paul B Manning
10% owner
—
—
—
2,841,704
$17.73M
+35.9%
Kamran Alam
Chief Financial Officer
—
—
—
1,442,131
$9.00M
+71.5%
John A Stalfort III
Director
—
—
—
1,176,559
$7.34M
+7.1%
Sukumar Nagendran
President and Head of R&D
—
—
—
936,410
$5.84M
+4.3%
Phillip B. Donenberg
Director
—
—
—
241,289
$1.51M
+47.7%
Alison S Long
Director
—
—
—
127,178
$793.59K
+158.4%
Laura Sepp-Lorenzino
Director
—
—
—
127,178
$793.59K
+158.4%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.